JP4216013B2 - Anti-influenza virus agent - Google Patents
Anti-influenza virus agent Download PDFInfo
- Publication number
- JP4216013B2 JP4216013B2 JP2002217441A JP2002217441A JP4216013B2 JP 4216013 B2 JP4216013 B2 JP 4216013B2 JP 2002217441 A JP2002217441 A JP 2002217441A JP 2002217441 A JP2002217441 A JP 2002217441A JP 4216013 B2 JP4216013 B2 JP 4216013B2
- Authority
- JP
- Japan
- Prior art keywords
- influenza virus
- extract
- infection
- present
- virus agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700605 Viruses Species 0.000 title claims description 23
- 206010022000 influenza Diseases 0.000 title claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- 244000208874 Althaea officinalis Species 0.000 claims description 8
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 8
- 240000008554 Aloysia triphylla Species 0.000 claims description 7
- 235000013668 Aloysia triphylla Nutrition 0.000 claims description 7
- 241001310324 Cetraria islandica Species 0.000 claims description 7
- 235000011430 Malus pumila Nutrition 0.000 claims description 6
- 235000015103 Malus silvestris Nutrition 0.000 claims description 6
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 6
- 244000070406 Malus silvestris Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 235000011446 Amygdalus persica Nutrition 0.000 claims description 4
- 240000006122 Chenopodium album Species 0.000 claims description 4
- 235000009344 Chenopodium album Nutrition 0.000 claims description 4
- 235000008730 Ficus carica Nutrition 0.000 claims description 4
- 244000025361 Ficus carica Species 0.000 claims description 4
- 244000144730 Amygdalus persica Species 0.000 claims description 3
- 241001113925 Buddleja Species 0.000 claims description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 2
- 240000000982 Malva neglecta Species 0.000 claims 1
- 235000000060 Malva neglecta Nutrition 0.000 claims 1
- 244000184734 Pyrus japonica Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000419 plant extract Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 240000005809 Prunus persica Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 5
- 241000220225 Malus Species 0.000 description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
- 240000003444 Paullinia cupana Species 0.000 description 5
- 235000000556 Paullinia cupana Nutrition 0.000 description 5
- 101710176177 Protein A56 Proteins 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 235000021016 apples Nutrition 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 235000001035 marshmallow Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000011305 Capsella bursa pastoris Nutrition 0.000 description 2
- 240000008867 Capsella bursa-pastoris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101800004637 Communis Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000912433 Paulinia Species 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 241000722946 Acanthocybium solandri Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 240000007108 Fuchsia magellanica Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 244000172533 Viola sororia Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/21—Binding agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Description
【０００１】
【発明の属する技術分野】
本発明は、インフルエンザウイルスの感染抑制作用を有する植物由来の抽出物を有効成分とすることを特徴とする抗インフルエンザウイルス剤に関するものである。
【０００２】
【従来の技術】
毎年のようにインフルエンザの流行を引き起こすインフルエンザウイルスは、直径１万分の１ミリメートル程度のエンベロープ膜を有するＲＮＡウイルスである。その抗原性の違いからＡ、Ｂ、Ｃの３つの型に分類されるが、流行的な広がりをみせるのはＡ型、Ｂ型である。これらのウイルスの粒子表面には、赤血球凝集素（ＨＡ）とノイラミニダーゼ（ＮＡ）という２種類の糖蛋白がスパイク状に突き出しており、内部には８本に分節した遺伝子ＲＮＡが存在する。ウイルスの表面にあるＨＡとＮＡは同一の亜型内で変異を頻繁に起こし、毎年のように新しい抗原変異株が出現する。
【０００３】
咳による飛沫によって放出されたインフルエンザウイルスは、ヒトの鼻や口から侵入し、ウイルス表層のスパイク状糖蛋白質ＨＡにより上気道の粘膜上皮細胞に吸着し、細胞へ侵入後増殖を開始する。近年の研究により、ウイルスの感染メカニズムが明らかにされている。ウイルスは、ヒトの標的細胞の表層に存在する糖鎖よりなるレセプターに結合し、エンドゾームへ取り込まれ、ウイルス膜とエンドゾーム膜の融合により細胞内に侵入し、ウイルス遺伝子の転写と複製、さらに宿主細胞膜からの出芽により子孫ウイルス粒子を形成し増殖する。
【０００４】
インフルエンザウイルスの感染により数日で突然の発熱、頭痛、関節の痛み、全身倦怠感等の症状が現れ、それと前後して咳や喉の痛み、鼻水、鼻づまりなどの呼吸器症状が出現する。いわゆる風邪とは異なり、感染力が強く短期間で爆発的な流行を引き起こすのが特徴である。またインフルエンザウイルスのＨＡ蛋白質の構造は年ごとに変異を繰り返し、過去の感染によりできた抗体があまり役に立たないことも感染を広げてしまう要因になっている。
【０００５】
インフルエンザウイルスの感染を抑制するためには、上皮細胞への吸着の阻害、細胞への侵入の阻害、遺伝子の転写・複製の抑制、蛋白質の合成阻害、細胞からの放出の抑制などが考えられ、それぞれが抗ウイルス薬のターゲットになっている。現在までに、アマンタジン、リマンタジン、ザナミビル等の抗ウイルス薬が開発されているが、過敏症、精神神経症状、消化器系症状、自律神経系症状等の副作用が報告されており、その応用に関しては注意が必要である。
【０００６】
またインフルエンザウイルスは気道粘膜上皮で感染、増殖することや、その年の流行型が予想できないことから、ワクチンの接種によって感染を抑えることも困難であると考えられている。頻繁なうがいと、喉の乾燥を避けること、栄養と休息を十分にとることなどが、現在最も有効な予防策と考えられている。そのため、感染抑制効果が高く、さらに安全性に問題がなく、日常的に利用できる抗インフルエンザウイルス剤の開発が望まれている。
【０００７】
近年、天然物由来の抗インフルエンザ素材としてお茶や紅茶のポリフェノール成分が報告されており（感染症学雑誌, 68 (7) 824-829 (1994)、感染症学雑誌, 70 (11) 1190-1192 (1996)）、人を用いた試験により紅茶のうがいが実際のウイルス感染を抑えることが明らかになっている（感染症学雑誌, 71 (6) 487-494 (1997)）。またオウゴン由来のフラボノイド成分が、ウイルスのシアリダーゼ阻害活性によりインフルエンザ感染抑制効果を示すことが報告されている（Chem. Pharm. Bull. 38(5) 1329-1332 (1990)）。さらに漢方製剤である桂枝二越婢一湯（特開平６−１９９６８０）、黒房すぐり抽出物（特開２０００−２１２０９２）、馬鈴薯アントシアニン色素（特開２００１−３１６３９９）、グァバ葉抽出物（特開２０００−２７３０４８）羅布麻抽出物（特開平１１−７１２９６）等の抗ウイルス効果が報告されているが、本発明に示された植物抽出物のインフルエンザウイルス感染抑制効果に関する報告はみられず、本発明により初めて明らかにされたものである。
【０００８】
【発明が解決しようとする課題】
本発明は、日常的に安心して使用できる安全性の高い植物抽出物を用いて、インフルエンザウイルスの感染に対して高い抑制効果を示し、副作用の無い抗インフルエンザウイルス剤を提供することである。
【０００９】
【課題を解決するための手段】
上記課題を解決するために、本発明者らは副作用がなく安全性の高い古くより食品や香料、お茶などに利用されてきた植物や生薬、ハーブなどに着目し、これらの中から抗インフルエンザウイルス作用を有する植物抽出物を見出すため、インフルエンザウイルス（Ｈ３Ｎ２）のＭＤＣＫ細胞に対する感染性の抑制効果を指標に試験を実施した。
【００１０】
その結果、イチジク（Ｆｉｃｕｓ ｃａｒｉｃａ）、アカザ（Ｃｈｅｎｏｐｏｄｉｕｍ ａｌｂｕｍ）、モモ（Ｐｒｕｎｕｓ ｐｅｒｓｉｃａ）、リンゴ（Ｍａｌｕｓ ｐｕｍｉｌａ）、ガラナ（Ｐａｕｌｌｉｎｉａ ｃｕｐａｎａ）、ワタフジウツギ（Ｂｕｄｄｌｅｉａ ｏｆｆｉｃｉｎａｌｉｓ）、ツユクサ（Ｃｏｍｍｅｌｉｎａ ｃｏｍｍｕｎｉｓ）、ナズナ（Ｃａｐｓｅｌｌａ ｂｕｒｓａ−ｐａｓｔｏｒｉｓ）、マーシュマロー（Ａｌｔｈａｅａ ｏｆｆｉｃｉｎａｌｉｓ）、レモンバーベナ（Ａｌｏｙｓｉａ ｔｒｉｐｈｙｌｌａ）、アイスランドモス（Ｃｅｔｒａｒｉａ ｉｓｌａｎｄｉｃａ）、アマチャヅル（Ｇｙｎｏｓｔｅｍｍａ ｐｅｎｔａｐｈｙｌｌｕｍ）、フキ（Ｐｅｔａｓｉｔｅｓ ｊａｐｏｎｉｃｕｓ）の抽出物が強いインフルエンザウイルスの感染抑制効果を有することを見出し、本発明を完成させた。
【００１１】
すなわち本発明は、イチジク（Ｆｉｃｕｓ ｃａｒｉｃａ）、アカザ（Ｃｈｅｎｏｐｏｄｉｕｍ ａｌｂｕｍ）、モモ（Ｐｒｕｎｕｓ ｐｅｒｓｉｃａ）、リンゴ（Ｍａｌｕｓ ｐｕｍｉｌａ）、ガラナ（Ｐａｕｌｌｉｎｉａ ｃｕｐａｎａ）、ワタフジウツギ（Ｂｕｄｄｌｅｉａ ｏｆｆｉｃｉｎａｌｉｓ）、ツユクサ（Ｃｏｍｍｅｌｉｎａ ｃｏｍｍｕｎｉｓ）、ナズナ（Ｃａｐｓｅｌｌａ ｂｕｒｓａ−ｐａｓｔｏｒｉｓ）、マーシュマロー（Ａｌｔｈａｅａ ｏｆｆｉｃｉｎａｌｉｓ）、レモンバーベナ（Ａｌｏｙｓｉａ ｔｒｉｐｈｙｌｌａ）、アイスランドモス（Ｃｅｔｒａｒｉａ ｉｓｌａｎｄｉｃａ）、アマチャヅル（Ｇｙｎｏｓｔｅｍｍａ ｐｅｎｔａｐｈｙｌｌｕｍ）、フキ（Ｐｅｔａｓｉｔｅｓ ｊａｐｏｎｉｃｕｓ）からなる群より選択される１種の植物から抽出することより得られる抽出物を有効成分とすることを特徴とする抗インフルエンザウイルス剤である。
【００１３】
【発明の実施の形態】
本発明品の原料となる植物、イチジク（Ｆｉｃｕｓ ｃａｒｉｃａ）、アカザ（Ｃｈｅｎｏｐｏｄｉｕｍ ａｌｂｕｍ）、モモ（Ｐｒｕｎｕｓ ｐｅｒｓｉｃａ）、リンゴ（Ｍａｌｕｓ ｐｕｍｉｌａ）、ガラナ（Ｐａｕｌｌｉｎｉａ ｃｕｐａｎａ）、ワタフジウツギ（Ｂｕｄｄｌｅｉａ ｏｆｆｉｃｉｎａｌｉｓ）、ツユクサ（Ｃｏｍｍｅｌｉｎａ ｃｏｍｍｕｎｉｓ）、ナズナ（Ｃａｐｓｅｌｌａ ｂｕｒｓａ−ｐａｓｔｏｒｉｓ）、マーシュマロー（Ａｌｔｈａｅａ ｏｆｆｉｃｉｎａｌｉｓ）、レモンバーベナ（Ａｌｏｙｓｉａ ｔｒｉｐｈｙｌｌａ）、アイスランドモス（Ｃｅｔｒａｒｉａ ｉｓｌａｎｄｉｃａ）、アマチャヅル（Ｇｙｎｏｓｔｅｍｍａ ｐｅｎｔａｐｈｙｌｌｕｍ）、フキ（Ｐｅｔａｓｉｔｅｓ ｊａｐｏｎｉｃｕｓ）は、その全体、葉、果実、花、材、樹皮、根等の部位を使用することができるが、イチジク、モモ、ツユクサ、ナズナ、マーシュマロー、レモンバーベナ、フキについては葉を、またアカザ、アイスランドモスについてはその全体を、リンゴについてはその果実（未熟果）を、ワタフジウツギについては花を、ガラナについては種子を使用することが望ましい。
【００１４】
上記植物の粉砕物から本発明の抽出物を得る方法については特に限定しないが、水、メタノール、エタノール、ｎ−プロパノール並びにｎ−ブタノール等の低級アルコール、エーテル、クロロホルム、酢酸エチル、アセトン、グリセリン、プロピレングリコール等の有機溶剤またはこれらを適宜混合した溶剤を、好ましくは親水性の有機溶剤またはこれらを適宜混合した溶剤を用いて抽出することができる。しかし、本発明の抗インフルエンザウイルス剤を経口で摂取することを考慮すると、安全性の面から水、エタノールもしくはその混合液を用いて抽出することが望ましい。
【００１５】
抽出条件としては特に制限はないが、５０〜８０℃で１〜５時間程度が望ましい。抽出液を濾過し、抽出溶剤を留去したあと、減圧下において濃縮または凍結乾燥したものを使用することができる。また、これらの抽出物を有機溶剤分画、カラムクロマトグラフィー等により分画精製したものも使用することができる。
【００１６】
本発明品の投与方法については特に制限はないが、経口投与以外に気道投与、静脈内投与、直腸投与、皮下投与、皮内投与等を例示することができ、成人への投与量は各抽出物で１０〜２０００ｍｇ／日が好ましいが、この値に制限されるものではない。
【００１７】
本発明品である抗インフルエンザウイルス剤は、有効成分として例示した植物抽出物を溶剤もしくは分散剤等で適宜希釈調製して用いることもできる。また、場合により製剤用担体、乳化剤、希釈剤、安定剤等を添加することによりうがい薬、含漱剤、吸入剤、トローチ剤、散剤、錠剤、座剤、注射剤等、任意の製剤として利用することができる。この場合、抽出物の添加量としては、その形態によって異なるが、０．００１重量％以上、好ましくは約０．０１重量％以上の割合になるように添加するのが好適である。
【００１８】
また、本発明の抗インフルエンザウイルス剤を、マスク、エアコンフィルター、衣類、ウエットティシュ、スプレー等に吸着、含浸、添加することにより、インフルエンザ予防に寄与しうる組成物を提供することができる。これらの用途における植物抽出物の吸着、含浸、添加する量は、その組成物の形態に応じて異なり、一概に規定することは困難であるが、０．００１〜５重量％の割合になるように添加するのが好適である。
【００１９】
さらに、本発明の抗インフルエンザウイルス剤の有効成分である植物抽出物は安全性が高いことから、例えばチューインガム、キャンディ、錠菓、グミゼリー、チョコレート、ビスケット等の菓子、アイスクリーム、シャーベット、氷菓等の冷菓、飲料、スープ、ジャム等の飲食物に配合し、日常的に利用することが可能である。添加量としては、その利用形態および抽出物の呈味性によって異なるが、飲食品に対して０．００１〜５重量％、好ましくは約０．０１〜１重量％の割合になるように添加するのが好適である。
【００２０】
【実施例】
以下実施例、試験例を挙げて本発明を具体的に説明するが、本発明はこれらに限定されるものではない。
【００２１】
〔実施例１〕植物抽出物の調製
破砕した各種植物（ラズベリー、ストロベリー、ブラックベリー、イチジク、アカザ、アグリモニー、ユーカリ、モモ、リンゴ、ヴァイオレット、クロモジ、ガラナ、ワタフジウツギ、ツユクサ、ナズナ、エンメイソウ、ワイルドストロベリー、ホアハウンド、マーシュマロー、オオバコ、レモンバーベナ、ヤロー、アイスランドモス、アマチャヅル、フキ）それぞれ５０ｇに５００ｍｌの抽出溶剤（水、５０％エタノール、１００％エタノール、アセトン、酢酸エチル）を加え、３時間還流抽出を行った。得られた抽出液を濾別し、濃縮、凍結乾燥することにより、本発明品である植物抽出物を得ることができる。各植物の使用部位、抽出溶剤及び得られた抽出物の収率を表１に示した。
【００２２】
【表１】
〔試験例１〕
実施例１で示した本発明品である抽出物を試料として、インフルエンザウイルス感染抑制効果を調べた。インフルエンザウイルスはＡ／Ｕｄｏｒｎ／３０７／７２(Ｈ３Ｎ２)株を用いた。試料をジメチルスルフォキシドに溶解（５０ｍｇ／ｍｌ）したものを試料原液とした。試料原液をTris-Glucose-Saline（ＴＧＳ）で１０倍段階希釈し（１０６倍希釈まで）、これらの試料希釈液とウイルス液（１０００ＰＦＵ（plaque forming unit）／ｍｌ）を１：１に混合して室温で３０分間反応させた。この０．１ｍｌをMadin-Darby canine kidney（ＭＤＣＫ）細胞の単層培養（直径３５ｍｍシャーレ）に接種し、ウイルスを室温で１時間吸着させ、２ｍｌのＬ−１５アガロース培地を流し込み固めて３４℃、３日間培養し、生じたプラーク数を計測した。プラーク数がＴＧＳ処理コントロールの５０％以下となる試料の希釈倍数を感染中和価とした。実施例１で調製した本発明品である抽出物のインフルエンザウイルス感染抑制活性（感染中和価）を、以下の表２に示した。本発明品であるこれらの抽出物はいずれも感染中和価が１０５以上であり、強いウイルス感染抑制効果を示した。
【００２４】
【表２】
実施例１で調製した植物抽出物を用いて、うがい薬、吸入剤、トローチ剤、スプレー、チューインガム、キャンディ、錠菓、飲料を調製した。以下に実施例としてその処方を示した。
【００２６】
【発明の効果】
本発明品の抗インフルエンザウイルス剤は、安全性の高い天然物の抽出物を含有することを特徴とし、インフルエンザウイルスに対して強い感染抑制作用を有するものである。また、本発明の抗インフルエンザウイルス剤は、安全性が高いことから、マスク、エアコンフィルター、衣類、ウエットティッシュ、スプレー等に吸着、含浸、添加することにより、抗インフルエンザウイルス組成物として日常生活において広く利用することができる。さらに、チューインガム、キャンディ、錠菓、飲料等の飲食物に添加し、抗インフルエンザウイルス作用を有する飲食物として日常的に利用、摂取することも可能である。そのため、本発明の抗インフルエンザウイルス剤及びそれを含む組成物並びに飲食物はインフルエンザウイルスの感染予防や、インフルエンザウイルスに起因する疾病症状の緩和に有効である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an anti-influenza virus agent characterized by containing, as an active ingredient an extract from a plant having an infection inhibiting activity of influenza virus.
[0002]
[Prior art]
The influenza virus that causes the influenza epidemic every year is an RNA virus having an envelope membrane with a diameter of about 1 / 10,000 mm. Although it is classified into three types, A, B, and C, due to the difference in antigenicity, it is A type and B type that show a trendy spread. Two types of glycoproteins, hemagglutinin (HA) and neuraminidase (NA), protrude in the form of spikes on the surface of these virus particles, and gene RNA segmented into 8 segments exists inside. HA and NA on the surface of the virus frequently mutate within the same subtype, and new antigenic variants appear every year.
[0003]
The influenza virus released by the cough droplets enters from the human nose and mouth, adsorbs to the mucosal epithelial cells of the upper respiratory tract by the spike-like glycoprotein HA on the surface of the virus, and starts to proliferate after entering the cells. Recent research has revealed the mechanism of viral infection. A virus binds to a receptor consisting of a sugar chain on the surface of a human target cell, is taken into the endosome, enters the cell by fusion of the viral membrane and the endosomal membrane, transcription and replication of the viral gene, and further the host cell membrane Progeny virus particles form and propagate by budding.
[0004]
Infection of influenza virus causes symptoms such as sudden fever, headache, joint pain, general malaise in a few days, followed by respiratory symptoms such as cough, sore throat, runny nose and stuffy nose. Unlike the so-called cold, it is highly infectious and causes an explosive epidemic in a short period of time. In addition, the structure of the HA protein of influenza virus repeats mutations every year, and the fact that antibodies produced by past infections are not very useful is also a factor that spreads infection.
[0005]
In order to suppress infection with influenza virus, inhibition of adsorption to epithelial cells, inhibition of entry into cells, inhibition of gene transcription / replication, inhibition of protein synthesis, inhibition of release from cells, etc. are considered. Each is a target for antiviral drugs. To date, antiviral drugs such as amantadine, rimantadine, and zanamivir have been developed, but side effects such as hypersensitivity, neuropsychiatric symptoms, digestive system symptoms, and autonomic nervous system symptoms have been reported. Caution must be taken.
[0006]
In addition, influenza viruses are thought to be difficult to control by vaccination because influenza viruses infect and proliferate in the airway mucosal epithelium and the epidemic type of the year cannot be predicted. Frequent gargling, avoiding throat dryness, and adequate nutrition and rest are currently considered the most effective preventive measures. Therefore, it is desired to develop an anti-influenza virus agent that has a high infection-suppressing effect, has no safety problem, and can be used on a daily basis.
[0007]
In recent years, polyphenol components of tea and black tea have been reported as anti-influenza materials derived from natural products (Journal of Infectious Diseases, 68 (7) 824-829 (1994), Journal of Infectious Diseases, 70 (11) 1190-1192 (1996)), it has been clarified that gargle of black tea suppresses actual viral infections by human tests (Journal of Infectious Diseases, 71 (6) 487-494 (1997)). In addition, it has been reported that a flavonoid component derived from urgonum exhibits an influenza infection suppression effect due to a virus sialidase inhibitory activity (Chem. Pharm. Bull. 38 (5) 1329-1332 (1990)). Furthermore, Kameda Futoshi Koshiketsuto (Japanese Patent Laid-Open No. Hei 6-199680), Kurofu currant extract (Japanese Patent Laid-Open No. 2000-212092), potato anthocyanin pigment (Japanese Patent Laid-Open No. 2001-316399), guava leaf extract (specialty) Open 2000-273048) Rafu hemp extract (Japanese Patent Laid-Open No. 11-71296) has been reported to have an antiviral effect, but no report on the influenza virus infection inhibitory effect of the plant extract shown in the present invention has been found, This has been revealed for the first time by the present invention.
[0008]
[Problems to be solved by the invention]
An object of the present invention is to provide an anti-influenza virus agent that exhibits a high inhibitory effect against influenza virus infection and has no side effects, using a highly safe plant extract that can be used with peace of mind on a daily basis.
[0009]
[Means for Solving the Problems]
In order to solve the above problems, the present inventors have focused on plants, herbal medicines, herbs, etc. that have been used for foods, fragrances, teas, etc., since they have no side effects and are highly safe. In order to find a plant extract having an action, a test was carried out using as an index the inhibitory effect of influenza virus (H3N2) on the infectivity of MDCK cells.
[0010]
As a result, figs (Ficus carica), red crows (Chenopodium album), peaches (Prunus persica), apples (Malus pumila), guarana (Paulinia cupana), buddujia sasa (Buddleia sap) -Pastoris, Martha Mallow (Althaea officinalis), Lemon Verbena (Aloysia triphylla), Icelandic moss (Cetraria islandica), Gynostemma pentaphyllum, Jessica (Peto), pesto The present invention was completed by finding that it has an inhibitory effect on Nzavirus infection.
[0011]
That is, the present invention relates to figs (Ficus carica), akaza (Chenopodium album), peaches (Prunus persica), apples (Malus pumila), guarana (Paulinia cupana), buddulina Comma (Buddulina). From Capsella bursa-pastoris, Marshmallow (Althaea officinalis), Lemon Verbena (Aloysia triphylla), Iceland moss (Cetriaria islandica), Gammastemma pentaphyl It is an anti-influenza virus agent characterized by using an extract obtained by extracting from one selected plant as an active ingredient.
[0013]
DETAILED DESCRIPTION OF THE INVENTION
Plants from which the product of the present invention is made, figs (Ficus carica), red peas (Chenopodium album), peaches (Prunus persica), apples (Malus pumila), guarana (Paullinia cupana), cotton codice (a) ), Nazuna (Capsella bursa-pastoris), Marshmallow (Althaea officinalis), Lemon Verbena (Aloysia triphylla), Iceland moss (Cetraria islandica, et al.) Whole, leaves, fruits, flowers, timber, bark, roots, etc. can be used, but for figs, peaches, communis, nazuna, marsh mallow, lemon verbena, fuchsia leaves, akaza, iceland moss its entirety for, the fruit (unripe) for apples, flowers for Watafujiutsugi, it is desirable for the gas Rana to use seeds.
[0014]
The method for obtaining the extract of the present invention from the above pulverized plant is not particularly limited, but water, methanol, ethanol, lower alcohols such as n-propanol and n-butanol, ether, chloroform, ethyl acetate, acetone, glycerin, An organic solvent such as propylene glycol or a solvent appropriately mixed with these can be extracted, preferably using a hydrophilic organic solvent or a solvent appropriately mixed with these. However, in consideration of taking the anti-influenza virus agent of the present invention orally, it is desirable to extract using water, ethanol or a mixture thereof from the viewpoint of safety.
[0015]
There are no particular limitations on the extraction conditions, but it is preferably about 1 to 5 hours at 50 to 80 ° C. The extract can be filtered and the extraction solvent can be distilled off, followed by concentration or lyophilization under reduced pressure. Further, those obtained by fractionating and purifying these extracts by organic solvent fractionation, column chromatography or the like can also be used.
[0016]
There are no particular restrictions on the administration method of the product of the present invention, but airway administration, intravenous administration, rectal administration, subcutaneous administration, intradermal administration, etc. can be exemplified in addition to oral administration. Although 10 to 2000 mg / day is preferable, it is not limited to this value.
[0017]
The anti-influenza virus agent which is the product of the present invention can be used by appropriately diluting and preparing a plant extract exemplified as an active ingredient with a solvent or a dispersant. In some cases, it can be used as an optional preparation such as mouthwash, gargle, inhalant, troche, powder, tablet, suppository, injection, etc. by adding pharmaceutical carriers, emulsifiers, diluents, stabilizers, etc. can do. In this case, the amount of the extract to be added varies depending on the form, but it is preferable that the extract is added in an amount of 0.001 wt% or more, preferably about 0.01 wt% or more.
[0018]
Moreover, the composition which can contribute to influenza prevention can be provided by adsorb | sucking, impregnating, and adding the anti-influenza virus agent of this invention to a mask, an air-conditioner filter, clothing, wet tissue, a spray etc. The amount of adsorbed, impregnated and added plant extract in these applications varies depending on the form of the composition and is difficult to define in general, but it will be in the proportion of 0.001 to 5% by weight. It is suitable to add to.
[0019]
Furthermore, since the plant extract which is an active ingredient of the anti-influenza virus agent of the present invention has high safety, for example, chewing gum, candy, tablet confectionery, gummy jelly, chocolate, biscuits and other confectionery, ice cream, sorbet, ice confectionery etc. It can be blended into foods and drinks such as frozen desserts, beverages, soups and jams and used on a daily basis. The amount added varies depending on the form of use and the taste of the extract, but it is added in an amount of 0.001 to 5% by weight, preferably about 0.01 to 1% by weight, based on the food or drink. Is preferred.
[0020]
【Example】
EXAMPLES The present invention will be specifically described below with reference to examples and test examples, but the present invention is not limited to these examples.
[0021]
[Example 1] Preparation of plant extract Various crushed plants (raspberry, strawberry, blackberry, fig, red aza, agrimony, eucalyptus, peach, apple, violet, black moji, guarana, cotton bud, communis, nazuna, emmeiso, wild Add 500 ml of extraction solvent (water, 50% ethanol, 100% ethanol, acetone, ethyl acetate) to 50 g each of strawberry, hoahound, marsh mallow, plantain, lemon verbena, yarrow, iceland moss, amacha eel, burdock) for 3 hours Reflux extraction was performed. The obtained extract is filtered, concentrated and freeze-dried to obtain the plant extract as the product of the present invention. Table 1 shows the use site of each plant, the extraction solvent, and the yield of the extract obtained.
[0022]
[Table 1]
[Test Example 1]
Using the extract, which is the product of the present invention shown in Example 1, as a sample, the influenza virus infection inhibitory effect was examined. As the influenza virus, A / Udon / 307/72 (H3N2) strain was used. A sample stock solution was prepared by dissolving a sample in dimethyl sulfoxide (50 mg / ml). The sample stock solution Tris-Glucose-Saline (TGS) at ten-fold serial dilutions (10 to 6 fold dilution), these sample diluent and virus solution (1000PFU (plaque forming unit) / ml) 1: mixture 1 And reacted at room temperature for 30 minutes. 0.1 ml of this was inoculated into a monolayer culture (35 mm diameter petri dish) of Madin-Darby canine kidney (MDCK) cells, the virus was adsorbed at room temperature for 1 hour, and 2 ml of L-15 agarose medium was poured and solidified at 34 ° C. After culturing for 3 days, the number of plaques produced was counted. The dilution multiple of the sample in which the number of plaques was 50% or less of the TGS-treated control was taken as the infection neutralization value. The influenza virus infection inhibitory activity (infection neutralization value) of the extract of the present invention prepared in Example 1 is shown in Table 2 below. These extracts products of the present invention is any even infection neutralization number of 10 5 or more, it showed a strong viral infection inhibiting effect.
[0024]
[Table 2]
Using the plant extract prepared in Example 1, a mouthwash, inhalant, troche, spray, chewing gum, candy, tablet confectionery, and beverage were prepared. The prescription was shown as an Example below.
[0026]
【The invention's effect】
The anti-influenza virus agent of the present invention contains a highly safe natural product extract, and has a strong infection-suppressing action against influenza virus. Further, since the anti-influenza virus agent of the present invention has high safety, it is widely used in daily life as an anti-influenza virus composition by adsorbing, impregnating, and adding to a mask, air conditioner filter, clothing, wet tissue, spray, etc. Can be used. Furthermore, it can be added to foods and drinks such as chewing gum, candy, tablet confectionery, beverages, etc., and can be used and taken on a daily basis as foods and drinks having an anti-influenza virus action. Therefore, the anti-influenza virus agent of the present invention, the composition containing it, and food and drink are effective for preventing infection of influenza virus and alleviating disease symptoms caused by influenza virus.
Claims (1)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002217441A JP4216013B2 (en) | 2002-07-26 | 2002-07-26 | Anti-influenza virus agent |
| KR1020030051304A KR101165592B1 (en) | 2002-07-26 | 2003-07-25 | Anti-influenza viral agent, the composition and the food containing the same |
| KR1020100093459A KR101084552B1 (en) | 2002-07-26 | 2010-09-27 | Anti-influenza viral agent, the composition and the food containing the same |
| KR1020120009164A KR101254168B1 (en) | 2002-07-26 | 2012-01-30 | Anti-influenza viral agent, the composition and the food containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002217441A JP4216013B2 (en) | 2002-07-26 | 2002-07-26 | Anti-influenza virus agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004059463A JP2004059463A (en) | 2004-02-26 |
| JP4216013B2 true JP4216013B2 (en) | 2009-01-28 |
Family
ID=31938875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002217441A Expired - Fee Related JP4216013B2 (en) | 2002-07-26 | 2002-07-26 | Anti-influenza virus agent |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4216013B2 (en) |
| KR (3) | KR101165592B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022065983A3 (en) * | 2020-09-28 | 2022-05-19 | 한국한의학연구원 | Coronavirus infection preventing or treating composition comprising gynostemma pentaphyllum extract |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10359384A1 (en) * | 2003-12-18 | 2005-07-28 | Anoxymer Gmbh | Use of an extract of Aloysia triphylla as matrix protector |
| JP4669670B2 (en) * | 2004-06-04 | 2011-04-13 | 株式会社ロッテ | Anti-influenza virus agent and influenza infection suppression product obtained by adsorbing, impregnating and adding the same |
| JP4306586B2 (en) | 2004-10-26 | 2009-08-05 | トヨタ自動車株式会社 | Valve characteristic control device for internal combustion engine |
| JP5064731B2 (en) * | 2005-07-22 | 2012-10-31 | 株式会社ファンケル | Antihypertensive |
| HUP0500947A2 (en) * | 2005-10-14 | 2007-08-28 | Mendon Trade & Commerce Lc | Composition for treatment of paradontosis |
| JP5002588B2 (en) * | 2006-04-27 | 2012-08-15 | ユーハ味覚糖株式会社 | Arteriosclerosis inhibitor |
| GB0808974D0 (en) * | 2008-05-16 | 2008-06-25 | Veritron Ltd | Plant extract and its therapeutic use |
| JP5996837B2 (en) | 2010-05-28 | 2016-09-21 | 小林製薬株式会社 | Influenza virus infection inhibitor |
| JP5776364B2 (en) * | 2011-06-22 | 2015-09-09 | ライオン株式会社 | Antimicrobial agents, oral compositions and their applications |
| WO2013027245A1 (en) | 2011-08-24 | 2013-02-28 | 株式会社ロッテ | Influenza virus infection inhibitor |
| KR101647323B1 (en) * | 2014-09-05 | 2016-08-11 | 경상대학교 산학협력단 | Virucidal composition containing natural products for avian inflenza virus |
| RU2580305C1 (en) * | 2015-02-26 | 2016-04-10 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | ANTIVIRAL AGENT BASED ON DRY EXTRACT OF LICHEN Cetraria islandica |
| ES2811951T3 (en) * | 2015-04-01 | 2021-03-15 | Zeller Max Soehne Ag | Butterbur extract and composition to treat viral infections |
| CZ307823B6 (en) * | 2016-07-14 | 2019-05-29 | DG PHARMA, s.r.o. | Herbal extract and its use |
| JP2018118959A (en) * | 2017-01-20 | 2018-08-02 | 養命酒製造株式会社 | Antimicrobial composition having lindera umbellate as source material |
| WO2020017619A1 (en) | 2018-07-20 | 2020-01-23 | 株式会社 資生堂 | Virus inactivating agent |
| KR102386936B1 (en) * | 2020-01-15 | 2022-04-13 | 한국수목원정원관리원 | Composition containing extract of butterbur as an active ingredient for preventing, alleviating or treating sepsis |
| KR102540384B1 (en) * | 2022-10-25 | 2023-06-05 | 한국 한의학 연구원 | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component |
| US11813287B1 (en) | 2023-03-10 | 2023-11-14 | King Faisal University | Covid-19 binding aerosols |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4127875B2 (en) | 1997-06-11 | 2008-07-30 | 株式会社ロッテ | Anti-Helicobacter pylori |
| JP3978517B2 (en) | 1997-07-25 | 2007-09-19 | 株式会社ロッテ | Anti-Legionella composition |
| JP4013017B2 (en) * | 1999-01-22 | 2007-11-28 | 三栄源エフ・エフ・アイ株式会社 | Anti-fading agent for anthocyanin pigment and food containing the same |
| JP2001328941A (en) * | 2000-05-22 | 2001-11-27 | Yanai Yoshiaki | Antiviral agent |
-
2002
- 2002-07-26 JP JP2002217441A patent/JP4216013B2/en not_active Expired - Fee Related
-
2003
- 2003-07-25 KR KR1020030051304A patent/KR101165592B1/en not_active IP Right Cessation
-
2010
- 2010-09-27 KR KR1020100093459A patent/KR101084552B1/en active IP Right Grant
-
2012
- 2012-01-30 KR KR1020120009164A patent/KR101254168B1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022065983A3 (en) * | 2020-09-28 | 2022-05-19 | 한국한의학연구원 | Coronavirus infection preventing or treating composition comprising gynostemma pentaphyllum extract |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004059463A (en) | 2004-02-26 |
| KR20100121579A (en) | 2010-11-18 |
| KR20040010390A (en) | 2004-01-31 |
| KR101254168B1 (en) | 2013-04-18 |
| KR101165592B1 (en) | 2012-07-23 |
| KR20120027040A (en) | 2012-03-20 |
| KR101084552B1 (en) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4216013B2 (en) | Anti-influenza virus agent | |
| KR101139376B1 (en) | Anti influenza viral drug and, viral-infection suppression products and foods comprising the same | |
| US20070248700A1 (en) | Extractions and Methods Comprising Elder Species | |
| CA2721040C (en) | Procyanidin extracts of cinnamon, litchi and arachis useful in the treatment of retroviral infections | |
| JP2007524709A (en) | Scutellaria extract for treating SARS | |
| US8470378B2 (en) | Anti-influenza viral composition containing bark or stem extract of Alnus japonica | |
| KR101182824B1 (en) | Composition having anti-allergic activity containing Zanthoxylum piperitum DC fruit extract or glycoprotein isolated from its extract | |
| KR101501876B1 (en) | Composition for preventing or treating influenza virus infection comprising xylitol | |
| KR20210002378A (en) | Hepatoprotective composition containing pini pollen extract as effective component | |
| KR101778227B1 (en) | Composition for anti-obesity comprising extract of Morus alba as effective component | |
| JP5303482B2 (en) | Anti-influenza virus agent and influenza infection suppression product obtained by adsorbing, impregnating and adding the same | |
| JP5343016B2 (en) | Anti-influenza virus agent and influenza infection suppression product obtained by adsorbing, impregnating and adding the same | |
| WO2011036883A1 (en) | Anti-influenza virus agent | |
| JP2012229178A (en) | Pandemic influenza antiviral agent | |
| EP4151226A1 (en) | Coronavirus therapeutic agent comprising zanthoxylum piperitum leaf extract as active ingredient | |
| JP2012131823A (en) | Activator of ciliary movement, and food and drink containing the same | |
| US20220211792A1 (en) | Composition containing natural extracts for enhancement of innate immunity or antiviral use against influenza virus or corona virus | |
| TWI389700B (en) | A novel standardized composition, method of manufacture and use in the resolution of rna virus infection | |
| JP6901711B2 (en) | α-Glucosidase inhibitor and its use | |
| KR20210139180A (en) | Therapeutic agent for coronavirus comprising Zanthoxylum piperitum leaf extract as effective component | |
| KR20150144160A (en) | Composition for reducing body fat comprising xanthorrhizol or Java tumeric extract | |
| EP4216975A1 (en) | Synergistic herbal compositions for immunity, cold and cough | |
| KR20220161908A (en) | Composition for improving immunity or for antiviral | |
| JP2012131822A (en) | Activator of ciliary movement, and food and drink containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040604 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070622 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070628 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080513 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080802 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081008 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081105 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4216013 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111114 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141114 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |